8-K: EyePoint Pharmaceuticals Advances DURAVYU for Wet AMD with Positive Phase 2 Data and Phase 3 Trial Plans

EyePoint Pharmaceuticals announced positive 12-month results from its Phase 2 DAVIO 2 trial for DURAVYU in wet AMD and detailed plans for Phase 3 trials.

Summary

• EyePoint Pharmaceuticals held its R&D Day, highlighting the progress of its lead drug candidate, DURAVYU, for treating wet age-related macular degeneration (wet AMD).
• The company presented positive 12-month data from the Phase 2 DAVIO 2 trial, which showed that DURAVYU maintained visual acuity and provided strong anatomical control with a single injection.
• Approximately half of the patients treated with DURAVYU were supplement-free for up to 12 months, compared to 22% in the aflibercept control group who still required additional injections despite bi-monthly treatments.
• The company is moving forward with two Phase 3 pivotal trials, LUGANO (US) and LUCIA (US/Ex-US), expected to enroll around 400 patients each, with the first patient dosing anticipated in the second half of 2024.
• The Phase 3 trials will evaluate a 2.7mg dose of DURAVYU against aflibercept, with a primary endpoint of non-inferiority in visual acuity at 12 months.
• EyePoint also highlighted its early-stage pipeline, including EYP-2301, a TIE-2 agonist, and its proprietary Durasert E drug delivery technology.
• The company estimates it has approximately $280 million in cash and investments as of June 30, 2024, with no debt.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a clear path forward for Phase 3 trials, indicating a strong potential for the company's lead product. The company also has a strong cash position and no debt, which is a positive sign for investors. However, there are still risks associated with clinical trials and regulatory approvals, which prevents a perfect score.

Positives

• DURAVYU has shown a favorable safety profile with no drug-related ocular or systemic serious adverse events in clinical trials.
• The Durasert E technology allows for sustained drug release, potentially reducing the frequency of injections.
• The company has a clear regulatory pathway for Phase 3 trials, with FDA alignment on key design elements.
• The Phase 3 trials will include a broad patient population, including both previously treated and treatment-naive patients.
• The company has a commercial manufacturing facility built to US FDA and EU EMA standards.
• DURAVYU is a patented molecule with a new mechanism of action and best-in-class delivery technology.
• DURAVYU is shipped and stored at ambient temperature and is administered with a standard intravitreal injection.
• DURAVYU is immediately bioavailable with zero-order release kinetics for approximately nine months.

Negatives

• The financial results are preliminary and subject to change upon completion of the company's quarterly report.
• The timeline for potential FDA approval of DURAVYU is uncertain.
• The company is dependent on contract research organizations and other outside vendors.
• The company's stock price is subject to volatility.
• The company is subject to risks related to manufacturing, intellectual property, and regulatory approvals.

Risks

• The effectiveness and timeliness of clinical trials could impact the development timeline.
• Regulatory approvals may be delayed or not granted.
• The company may need to access additional capital in the future.
• There are risks associated with the termination or breach of current and future license agreements.
• The company is subject to competition from other companies developing treatments for retinal diseases.
• The company is subject to risks related to the volatility of its stock price and possible dilution.
• The company is subject to risks related to the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market.

Future Outlook

EyePoint anticipates initiating Phase 3 trials for DURAVYU in the second half of 2024 and believes DURAVYU and its earlier-stage programs are potentially multi-billion-dollar product opportunities. The company is focused on advancing its mission of improving patient vision with innovative treatment options.

Management Comments

• Jay Duker, M.D., President and CEO, stated that EyePoint is pioneering the development of sustained-release drug delivery treatments for serious retinal diseases with DURAVYU.
• Jay Duker, M.D., President and CEO, mentioned that the company has a track record of strong execution, establishing the most robust dataset among sustained delivery TKI programs in wet age-related macular degeneration.
• Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer, stated that the company is encouraged by the excellent safety and efficacy results from the Phase 2 DAVIO 2 trial.
• Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer, mentioned that the company believes there remains a significant opportunity for a safe and effective sustained delivery maintenance treatment in wet AMD.

Industry Context

The announcement is significant in the context of the broader industry trend towards developing more durable therapies for retinal diseases, aiming to reduce the treatment burden on patients and physicians. The current standard of care involves frequent injections of anti-VEGF drugs, which can be burdensome and lead to undertreatment. EyePoint's DURAVYU, with its sustained-release technology, aims to address this unmet need.

Comparison to Industry Standards

• The current standard of care for wet AMD involves frequent intravitreal injections of anti-VEGF drugs like aflibercept (Eylea) typically every 1-2 months.
• The Phase 2 DAVIO 2 trial results for DURAVYU show a significant reduction in treatment burden, with approximately half of the patients remaining supplement-free for up to 12 months after a single injection, which is a substantial improvement over the current standard.
• Other companies are also developing long-acting treatments for wet AMD, but EyePoint claims to have the most robust dataset among sustained delivery TKI programs.
• The Phase 3 trial design for DURAVYU includes re-dosing, which aligns with expected commercial use and is a key differentiator from some other long-acting treatments in development.
• The company is comparing DURAVYU to aflibercept in a non-inferiority trial, which is a common approach for demonstrating the efficacy of new treatments in this space.
• The company references the PULSAR trial for HD Eylea (16-week 8mg arm) which showed a -1.4 letter change in BCVA vs. 2mg Eylea, which is a useful comparison point for the DURAVYU results.

Stakeholder Impact

• Shareholders: The positive clinical trial results and Phase 3 trial plans are likely to be viewed favorably by investors, potentially increasing the company's stock value.
• Patients: DURAVYU has the potential to significantly reduce the treatment burden for patients with wet AMD, improving their quality of life.
• Physicians: DURAVYU could provide a more convenient and effective treatment option for physicians managing patients with wet AMD.
• Employees: The company's progress in clinical development and manufacturing could lead to job growth and opportunities for employees.
• Suppliers: The company's manufacturing facility and clinical trials could create opportunities for suppliers of materials and services.

Next Steps

• Initiate Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet AMD in the second half of 2024.
• Continue development of early-stage pipeline programs, including EYP-2301.
• Present data from clinical and preclinical studies at multiple upcoming medical conferences.
• Submit a New Drug Application (NDA) to the FDA for DURAVYU upon completion of the Phase 3 trials.

Key Dates

Keywords

DURAVYU, vorolanib, wet AMD, retinal diseases, Durasert E, sustained drug delivery, EYP-1901, EYP-2301, clinical trials, FDA, aflibercept, TIE-2 agonist, intravitreal injection, treatment burden